Skepta officially revealed his new sneaker collaboration with Puma, calling the deal "much better" than his previous partnership with Nike. He now earns royalties on each shoe sold.
Skepta Celebrates Puma Collaboration on Social Media, Highlights Royalties and Creative Freedom Compared to Nike
According to Complex, Skepta took to social media to express his gratitude, a sentiment shared by his fans and sneaker enthusiasts alike, for his current collaboration with the global sportswear brand.
On May 18, Skepta announced the debut of his first Puma line on X.
"My shoes are selling out again," he wrote. "It's a much better deal now that I get royalties from shoes sold. Thank you to everybody on this shoe journey with me. Literally my dream come true."
Skepta compared his relationship with Puma, claiming he earns royalties on every shoe sold, to his deal with Nike, the first brand to collaborate with Skepta on sneaker designs.
Without identifying Nike, Skepta stated that despite his numerous sneaker projects with the brand, the company "still treated me like an influencer because I haven't been to school for shoe design."
Skepta and Nike's debut shoe collaboration, which dropped in September 2017, was an iridescent Air Max 97. This marked a significant milestone in Skepta's career, as he signed a deal with Nike following the success of this collaboration. The partnership resulted in five more releases, including the Air Max 97/BW, Air Max Deluxe, Shox TL, Air Max Tailwind 5, and Phantom GT Elite FG, each one a testament to Skepta's unique design aesthetic and growing influence in the sneaker industry.
Skepta's Determination to prove himself in the sneaker industry is unwavering. He has time and again showcased his talent in Portland, the city Nike calls home. Now, he's in Nuremberg, with a much better situation for himself and his team, a testament to his resilience and success.
Skepta Unveils New Puma Sneaker After Weeks of Rumors, Highlighting Creative Freedom and Unique Design
Rumors about Skepta and Puma's new collaboration have been circulating for weeks. The grime musician first entered the sneaker market by partnering with Nike for the SK Air Line before signing with Puma in 2022. He made his debut with the company later that year with the RS-X, but amid his directorial debut and work on the Mas Tiempo brand, it seemed that activity with Puma had quieted down.
That changed late last month when the BBK icon created a finsta to document the behind-the-scenes process of planning the next partnership. As word spread, the shoe's popularity surged. The Forever Black shoe has been officially unveiled and is set to retail on May 18. Skepta was given significant creative freedom over the design, resulting in a distinctive silhouette.
The sneaker features circular cutouts that reveal black mesh underneath, a reflective design contrasting with the deep black, and the customary co-branding on the heel counter and tongue. Skepta drew inspiration from past Puma designs, incorporating metallic features, alternating yellow and orange laces, and an all-chrome packaging.
On May 18, the new Skepta x Puma collaboration will be available on the Puma website.
Photo: Paul Steuber/Unsplash


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
FDA Approves Mitapivat for Anemia in Thalassemia Patients
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



